Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Re-irradiation in Recurrent Glioblastoma
NCT03661723Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2018
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in glioblastoma (GBM), sponsored by Dana-Farber Cancer Institute. Started Sep 2018; status: completed.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03661723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03661723.